Elastagen has developed a synthetic version of the elastin protein, which is identical to that naturally present in the human body, with potential applications in skin rejuvenation, scar remodelling and tissue repair. The company's platform is based on tropoelastin, a critical component of tissues in the human body that require the ability to stretch and recoil, such as the skin, lungs, arteries and elastic ligaments. Elastagen’s products have demonstrated clinical efficacy in stretch marks, acne scars and wound repair applications. The company was founded following the acquisition of intellectual property rights to the elastin technology, which was developed by Prof Weiss at the University of Sydney. It has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups, and its operations have expanded from its Australian base to include production in Europe and clinical operations in the UK.